Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein

被引:96
|
作者
Sugiyama, Y [1 ]
Kato, Y [1 ]
Chu, XY [1 ]
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
关键词
irinotecan; biliary excretion; P-glycoprotein; cMOAT;
D O I
10.1007/s002800051078
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A frequent dose-limiting effect of irinotecan (CPT-11) is its gastrointestinal toxicity (diarrhea), which is thought to be related to biliary excretion of CPT-11 and its metabolites. Accordingly, we have investigated the mechanism of biliary excretion of these compounds. In vivo pharmacokinetic studies revealed that the biliary excretion of the four anionic forms of CPT-11 and its metabolites was reduced in Eisai hyperbilirubinemic rats, which carry a mutation of the hepatic canalicular multispecific organic anion transporter (cMOAT) gene. The protein encoded by this gene is expressed on the bile canalicular membrane and is responsible for the transport of organic anions into bile. Detailed analysis using isolated liver bile canalicular membrane vesicles to identify transport systems showed that cMOAT is responsible for biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN-38 glucuronide. The carboxylate form of SN-38 is transported by cMOAT alone. Transport of the high-affinity component of CPT-11 was inhibited by verapamil and PSC-833, but their effect on the transport of its low-affinity component was minimal. In addition, ATP dependence in the uptake of CPT-11 by membrane vesicles obtained from a P-glycoprotein (P-gp)-overexpressing cell line was observed. Thus P-gp may be responsible for transport of the high-affinity component of the carboxylate form of CPT-11.
引用
收藏
页码:S44 / S49
页数:6
相关论文
共 29 条
  • [1] Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein
    Yuichi Sugiyama
    Yukio Kato
    Xiao-yan Chu
    Cancer Chemotherapy and Pharmacology, 1998, 42 : S44 - S49
  • [2] Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats
    Chu, XY
    Kato, Y
    Niinuma, K
    Sudo, K
    Hakusui, H
    Sugiyama, Y
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, 281 (01): : 304 - 314
  • [3] Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats
    Chu, XY
    Kato, Y
    Sugiyama, Y
    CANCER RESEARCH, 1997, 57 (10) : 1934 - 1938
  • [4] The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs
    Kusuhara, H
    Suzuki, H
    Sugiyama, Y
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (09) : 1025 - 1040
  • [5] In Vitro Binding and Partitioning of Irinotecan (CPT-11) and its Metabolite, SN-38, in Human Blood
    Olivier Combes
    Jérôme Barré
    Jean-Claude Duché
    Laurent Vernillet
    Yves Archimbaud
    Michael P. Marietta
    Jean-Paul Tillement
    Saïk Urien
    Investigational New Drugs, 2000, 18 : 1 - 5
  • [6] In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood
    Combes, O
    Barré, J
    Duché, JC
    Vernillet, L
    Archimbaud, Y
    Marietta, MP
    Tillement, JP
    Urien, S
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 1 - 5
  • [7] Effect of P-Glycoprotein Modulator, Cyclosporin A, on the Gastrointestinal Excretion of Irinotecan and Its Metabolite SN-38 in Rats
    Kazuhiko Arimori
    Noriaki Kuroki
    Muneaki Hidaka
    Tomomi Iwakiri
    Keishi Yamasaki
    Manabu Okumura
    Hiroshige Ono
    Norito Takamura
    Masahiko Kikuchi
    Masahiro Nakano
    Pharmaceutical Research, 2003, 20 : 910 - 917
  • [8] Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats
    Arimori, K
    Kuroki, N
    Hidaka, M
    Iwakiri, T
    Yamasaki, K
    Okumura, M
    Ono, H
    Takamura, N
    Kikuchi, M
    Nakano, M
    PHARMACEUTICAL RESEARCH, 2003, 20 (06) : 910 - 917
  • [9] Uptake mechanism of irinotecan (CPT-11) and its metabolite (SN-38) by hamster intestinal cells.
    Kobayashi, K
    Bouscarel, B
    Matsuzaki, Y
    Ceryak, S
    Fromm, H
    GASTROENTEROLOGY, 1998, 114 (04) : A626 - A627
  • [10] Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients
    Spinel Karas
    Amy S. Etheridge
    Eleftheria Tsakalozou
    Jacqueline Ramírez
    Erika Cecchin
    Ron H.N. van Schaik
    Giuseppe Toffoli
    Mark J. Ratain
    Ron H.J. Mathijssen
    Alan Forrest
    Robert R. Bies
    Federico Innocenti
    The AAPS Journal, 22